Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Teva Pharmaceuticals (Switzerland)
Homepage:
tevapharm.ch
Parent institution:
Teva Pharmaceuticals (Israel)
ROR:
0136jw687
OpenAlex ID:
I4210100574
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
2018
·
Ralf Reilmann
, Andrew McGarry
, et al.
·
The Lancet Neurology
·
112
Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers
2020
·
Frank Schneider
, Margaret Bradbury
, et al.
·
Clinical and Translational Science
·
58
PDF
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome
2021
·
Barbara Coffey
, Joseph Jankovic
, et al.
·
JAMA Network Open
·
48
PDF
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome
2021
·
Joseph Jankovic
, Barbara Coffey
, et al.
·
JAMA Network Open
·
45
PDF
Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects
2018
·
Frank Schneider
, Lavi Erisson
, et al.
·
British Journal of Clinical Pharmacology
·
44
PDF
Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices
2019
·
Mark Forrest Gordon
, Igor D. Grachev
, et al.
·
Digital Biomarkers
·
43
Characterizing patient compliance over six months in remote digital trials of Parkinson’s and Huntington disease
2018
·
Shani Cohen
, Zeev Waks
, et al.
·
BMC Medical Informatics and Decision Making
·
41
PDF
Pridopidine, a clinic‐ready compound, reduces 3,4‐dihydroxyphenylalanine‐induced dyskinesia in Parkinsonian macaques
2018
·
Tom H. Johnston
, Michal Geva
, et al.
·
Movement Disorders
·
40
Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
2020
·
Frank Schneider
, David Stamler
, et al.
·
Clinical Pharmacology in Drug Development
·
37
PDF
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
2022
·
Samuel Frank
, Claudia Testa
, et al.
·
CNS Drugs
·
35
PDF
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease
2020
·
Andrew McGarry
, Peggy Auinger
, et al.
·
Journal of Huntington s Disease
·
28
A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod
2023
·
Andreas-Antonios Roussakis
, Marta Gennaro
, et al.
·
Brain Communications
·
24
PDF
Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study
2023
·
Joseph Jankovic
, Barbara Coffey
, et al.
·
Movement Disorders Clinical Practice
·
16
PDF
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study
2022
·
Robert A. Hauser
, Hadas Barkay
, et al.
·
Frontiers in Neurology
·
16
PDF
Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (P2.005)
2017
·
Karl Kieburtz
, G. Bernhard Landwehrmeyer
, et al.
·
Neurology
·
10
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine
2022
·
Robert A. Hauser
, Hadas Barkay
, et al.
·
Parkinsonism & Related Disorders
·
8
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
2024
·
Samuel Frank
, Karen E. Anderson
, et al.
·
Neurology and Therapy
·
4
PDF
Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study
2021
·
Samuel Frank
, Claudia M. Testa
, et al.
·
CNS Spectrums
·
4
PDF
152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents
2020
·
Joseph Jankovic
, Barbara Coffey
, et al.
·
CNS Spectrums
·
3
PDF
Long-Term Efficacy and Safety of Deutetrabenazine in Patients with Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist Use
2022
·
Robert A. Hauser
, Hadas Barkay
, et al.
·
CNS Spectrums
·
2
PDF
Effects of Long-Term Deutetrabenazine Treatment in Patients With Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders (P9-11.002)
2022
·
Mark Forrest Gordon
, Robert A. Hauser
, et al.
·
Neurology
·
1
Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders
2022
·
Robert A. Hauser
, Hadas Barkay
, et al.
·
CNS Spectrums
·
1
PDF
Long-Term Deutetrabenazine Treatment Is Associated With Continued Improvement in Tardive Dyskinesia in the Completed 3-Year Open-Label Extension Study
2021
·
Robert A. Hauser
, Hadas Barkay
, et al.
·
CNS Spectrums
·
1
PDF
Minimal Clinically Important Difference in AIMS Score Based on CGIC and PGIC in Patients With Tardive Dyskinesia Treated With Deutetrabenazine
2021
·
Hadas Barkay
, Robert A. Hauser
, et al.
·
CNS Spectrums
·
1
PDF
134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study
2020
·
Robert A. Hauser
, Hadas Barkay
, et al.
·
CNS Spectrums
·
1
PDF
Show more works
View as search
Works count:
33
Citation count:
678
Year
Topic
Type
